Chiara Cremolini, MD, PhD, University of Pisa, Pisa, Italy, discusses the impact of sidedness on the prognosis and treatment of patients with metastatic colorectal cancer (mCRC). Right-sided tumors are more aggressive and patients experience a poorer prognosis. Patients with right-sided tumors are also associated with increased molecular alterations driving intrinsic resistance to anti-EGFR monoclonal antibodies. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.